Bio-Techne (TECH) Retained Earnings (2009 - 2026)
Bio-Techne (TECH) posted quarterly Retained Earnings of $1.1 billion for Q1 2026, up 1495.69% year-over-year from $71.8 million in Q1 2025, and up 3.47% quarter-over-quarter from $1.1 billion in Q4 2025.
Analysis
Bio-Techne (TECH) Retained Earnings (2009 - 2026) Analysis & Trends
Bio-Techne's Retained Earnings history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 1495.69% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 1495.69% YoY), while the FY2025 annual figure was $1.1 billion, down 19.56% from the prior year.
- Retained Earnings for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Retained Earnings was $1.3 billion in Q3 2023, with the low at -$91.8 million in Q3 2022.
- The 5-year median for Retained Earnings is $1.1 billion (2025), against an average of $671.2 million.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings tumbled 106.93% in 2022, then soared 2106.0% in 2024.
- Bio-Techne's Retained Earnings stood at $1.2 billion in 2022, then grew by 5.12% to $1.3 billion in 2023, then gained by 2.01% to $1.3 billion in 2024, then retreated by 13.98% to $1.1 billion in 2025, then climbed by 3.47% to $1.1 billion in 2026.
- Business Quant data shows TECH's Retained Earnings at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn | 1.14 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Bn |
| Mar 31, 2026 | 1.15 Bn |
| Dec 31, 2025 | 1.11 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Mar 31, 2025 | 1.20 Bn |
| Dec 31, 2024 | 1.29 Bn |
| Sep 30, 2024 | 1.34 Bn |
| Jun 30, 2024 | 1.33 Bn |
| Mar 31, 2024 | 1.30 Bn |
| Dec 31, 2023 | 1.26 Bn |
| Sep 30, 2023 | 1.33 Bn |
| Jun 30, 2023 | 1.31 Bn |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.20 Bn |
| Sep 30, 2022 | 1.16 Bn |
| Jun 30, 2022 | 1.12 Bn |
| Mar 31, 2022 | 1.13 Bn |
| Dec 31, 2021 | 1.15 Bn |
| Sep 30, 2021 | 1.12 Bn |